Adherence in pediatric A
Not Applicable
Recruiting
- Conditions
- Acute lymphoblastic leukemia
- Registration Number
- JPRN-UMIN000045155
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with relapsed ALL. 2. Patients who can not provide informed consent. 3. Other reasons.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint of this study is the adherence of 6-MP.
- Secondary Outcome Measures
Name Time Method 1. the proportion of the patients with adherence higher than 90%. 2. Cluster analysis by drawing scatter plots of 6-MMP and 6-TGN concentrations. 3. Chronological changes of adherence.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does 6-mercaptopurine adherence influence molecular pathways in pediatric ALL patients?
What is the comparative effectiveness of 6-MP adherence versus standard-of-care regimens in pediatric ALL?
What biomarkers predict 6-MP adherence outcomes in JPRN-UMIN000045155 pediatric ALL study?
What adverse events are associated with 6-MP adherence in pediatric ALL and how are they managed?
How do 6-MP combination therapies compare to alternative thiopurines in pediatric ALL adherence studies?